Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations
重新利用溴隐亭治疗阿尔茨海默病中的Aβ代谢（REBRAnD）研究：一项随机、安慰剂对照、双盲、比较试验和开放标签扩展试验，旨在研究溴隐亭治疗伴有早老素1（PSEN1）突变的阿尔茨海默病的安全性和有效性。
期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2021-051343
Kondo, Takayuki; Banno, Haruhiko; Okunomiya, Taro; Amino, Yoko; Endo, Kayoko; Nakakura, Akiyoshi; Uozumi, Ryuji; Kinoshita, Akemi; Tada, Harue; Morita, Satoshi; Ishikawa, Hidehiro; Shindo, Akihiro; Yasuda, Ken; Taruno, Yosuke; Maki, Takakuni; Suehiro, Takashi; Mori, Kohji; Ikeda, Manabu; Fujita, Koji; Izumi, Yuishin; Kanemaru, Kazutomi; Ishii, Kenji; Shigenobu, Kazue; Kutoku, Yumiko; Sunada, Yoshihide; Kawakatsu, Shinobu; Shiota, Shunji; Watanabe, Toshifumi; Uchikawa, Osamu; Takahashi, Ryosuke; Tomimoto, Hidekazu; Inoue, Haruhisa
